Table 2.
Clinical and molecular characteristics of patients according to DOCK2 levels
| Characteristics | Chemotherapy group | Allo-HSCT group | |||||
|---|---|---|---|---|---|---|---|
| High DOCK2 (n = 42) |
Low DOCK2 (n = 43) |
P | High DOCK2 (n = 35) |
Low DOCK2 (n = 36) |
P | ||
| Age/years, median (range) | 66.5 (22-77) | 66 (33-88) | 0.324* | 51 (22-69) | 52.5 (18-72) | 0.890* | |
| Age group/n (%) | 0.311§ | 0.205§ | |||||
| < 60 years | 15 (35.7) | 11 (25.6) | 28 (80.0) | 24 (66.7) | |||
| ≥ 60 years | 27 (64.3) | 32 (74.4) | 7 (20.0) | 12 (33.3) | |||
| Gender/n (%) | 0.591§ | 0.288§ | |||||
| Male | 21 (50.0) | 24 (55.8) | 18 (51.4) | 23 (63.9) | |||
| Female | 21 (50.0) | 19 (44.2) | 17 (48.6) | 13 (36.1) | |||
| WBC/×109/L, median (range) | 15.2(1.0-171.9) | 12.3(0.7-297.4) | 0.329* | 30.9(1.2-223.8) | 27.7(0.6-90.4) | 0.200* | |
| BM blast/%, median (range) | 71 (30-97) | 74 (32-99) | 0.379* | 71 (34-100) | 70 (30-97) | 0.809* | |
| PB blast/%, median (range) | 23 (0-91) | 25 (0-98) | 0.972* | 48 (0-96) | 53 (0-90) | 0.801* | |
| FAB subtypes/n(%) | |||||||
| M0 | 4 (9.5) | 3 (7.0) | 0.713§ | 3 (8.6) | 6 (16.7) | 0.478§ | |
| M1 | 7 (16.7) | 13 (30.2) | 0.140§ | 14 (40.0) | 9 (25.0) | 0.177§ | |
| M2 | 12 (28.6) | 9 (20.9) | 0.414§ | 8 (22.9) | 10 (27.8) | 0.634§ | |
| M3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.8) | 1.000§ | ||
| M4 | 11 (26.2) | 9 (20.9) | 0.568§ | 8 (22.9) | 5 (13.9) | 0.329§ | |
| M5 | 7 (16.7) | 6 (14.0) | 0.728§ | 1 (2.9) | 3 (8.3) | 0.614§ | |
| M6 | 1 (2.4) | 0 (0.0) | 0.494§ | 0 (0.0) | 1 (2.8) | 1.000§ | |
| M7 | 0 (0.0) | 2 (4.7) | 0.494§ | 0 (0.0) | 1 (1.4) | 1.000§ | |
| Karyotype/n(%) | |||||||
| Normal | 21 (50.0) | 19 (44.2) | 0.591§ | 11 (29.7) | 23 (62.2) | 0.005§ | |
| Complex | 3 (7.1) | 9 (20.9) | 0.117§ | 7 (18.9) | 5 (13.5) | 0.528§ | |
| inv(16)/CBFβ-MYH11 | 6 (14.3) | 0 (0.0) | 0.012§ | 5 (13.5) | 0 (0.0) | 0.054§ | |
| 11q23/MLL | 0 (0.0) | 3 (7.0) | 0.241§ | 2 (5.4) | 1 (2.7) | 1.000§ | |
| t(15;17)/PML-RARA | 0 (0.0) | 0 (0.0) | 1 (2.7) | 1 (2.7) | 1.000§ | ||
| t(9;22)/BCR-ABL1 | 0 (0.0) | 1 (2.3) | 1.000§ | 2 (5.4) | 0 (0.0) | 0.493§ | |
| t(8;21)/RUNX1-RUNX1T1 | 4 (9.5) | 2 (4.7) | 0.433§ | 0 (0.0) | 1 (2.7) | 1.000§ | |
| Others | 8 (19.0) | 9 (20.9) | 0.828§ | 4 (10.8) | 2 (5.4) | 0.674§ | |
| Risk/n(%) | |||||||
| Good | 10 (23.8) | 2 (4.7) | 0.014§ | 5 (14.3) | 2 (5.6) | 0.260§ | |
| Intermediate | 26 (61.9) | 20 (46.5) | 0.154§ | 23 (65.7) | 17 (47.2) | 0.116§ | |
| Poor | 6 (14.3) | 19 (44.2) | 0.002§ | 6 (17.1) | 17 (47.2) | 0.007§ | |
| FLT3-ITD/n(%) | 0.366§ | 0.730§ | |||||
| Presence | 9 (21.4) | 6 (14.0) | 9 (25.7) | 8 (22.2) | |||
| Absence | 33 (78.6) | 37 (86.0) | 29 (78.4) | 28 (75.7) | |||
| NPM1/n(%) | 0.440§ | 0.246§ | |||||
| Mutation | 15 (35.7) | 12 (27.9) | 11 (31.4) | 7 (19.4) | |||
| Wildtype | 27 (64.3) | 31 (72.1) | 24 (68.6) | 29 (80.6) | |||
| CEBPA/n(%) | 0.557§ | 0.033§ | |||||
| Single mutation | 1 (2.4) | 2 (4.7) | 4 (11.4) | 1 (2.8) | |||
| Double mutation | 0 (0.0) | 0 (0.0) | 3 (8.6) | 0 (0.0) | |||
| Wild type | 41 (97.6) | 41 (95.3) | 28 (80.0) | 35 (97.2) | |||
| DNMT3A/n(%) | 0.859§ | 0.044§ | |||||
| Mutation | 11 (26.2) | 12 (27.9) | 12 (34.3) | 5 (13.9) | |||
| Wildtype | 31 (73.8) | 31 (72.1) | 23 (65.7) | 31 (86.1) | |||
| IDH1/IDH2/n(%) | 0.366§ | 0.730§ | |||||
| Mutation | 9 (21.4) | 6 (14.0) | 9 (25.7) | 8 (22.2) | |||
| Wildtype | 33 (78.6) | 37 (86.0) | 26 (74.3) | 28 (77.8) | |||
| RUNX1/n(%) | 0.156§ | 0.260§ | |||||
| Mutation | 6 (14.3) | 2 (4.7) | 2 (5.7) | 6 (16.7) | |||
| Wildtype | 36 (85.7) | 41 (95.3) | 33 (94.3) | 30 (83.3) | |||
| WT1/n(%) | 1.000§ | 0.478§ | |||||
| Mutation | 1 (2.4) | 1 (2.3) | 5 (14.3) | 3 (8.3) | |||
| Wildtype | 41 (97.6) | 42 (97.7) | 30 (85.7) | 33 (91.7) | |||
| MLL-PTD/n(%) | 0.360§ | 0.614§ | |||||
| Presence | 1 (2.4) | 4 (9.3) | 1 (2.9) | 3 (8.3) | |||
| Absence | 41 (97.6) | 39 (90.7) | 34 (97.1) | 33 (91.7) | |||
| NRAS/KRAS/n(%) | 0.505§ | 0.710§ | |||||
| Mutation | 7 (16.7) | 5 (11.6) | 4 (11.4) | 3 (8.3) | |||
| Wildtype | 35 (83.3) | 38 (88.4) | 31 (88.6) | 33 (91.7) | |||
| TET2/n(%) | 0.778§ | 1.000§ | |||||
| Mutation | 5 (11.9) | 6 (14.0) | 2 (5.7) | 2 (5.6) | |||
| Wildtype | 37 (88.1) | 37 (86.0) | 33 (94.3) | 34 (94.4) | |||
| TP53/n(%) | 0.049§ | 0.115§ | |||||
| Mutation | 2 (4.8) | 9 (20.9) | 0 (0.0) | 4 (11.1) | |||
| Wildtype | 40 (95.2) | 34 (79.1) | 35 (100.0) | 32 (88.9) | |||
| Relapse/n(%) | 0.227§ | 0.614§ | |||||
| Yes | 18 (42.9) | 13 (30.2) | 25 (71.4) | 23 (63.9) | |||
| No | 24 (57.1) | 30 (69.8) | 10 (28.6) | 13 (36.1) | |||
Abbreviations: WBC: white blood cell; BM: bone marrow; PB: peripheral blood; FAB: French American British.
*denotes Mann-Whitney U test; §denotes chi-square test.